One study by Mitchell et al. [89] demonstrated that ponatinib-resistant CML cells can develop BCR-ABL-independent resistance through alternative activation of the mTOR pathway. This evidence concerns the gene MTOR and chronic myelogenous leukemia, BCR-ABL1 positive.